<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126014">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01840774</url>
  </required_header>
  <id_info>
    <org_study_id>43929</org_study_id>
    <nct_id>NCT01840774</nct_id>
  </id_info>
  <brief_title>Modifying Virtual Reality Analgesia With Low-Dose Pain Medication</brief_title>
  <official_title>Modifying Virtual Reality Analgesia With Low-Dose Pain Medication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine how pain relief is modified when the investigators
      combine the Virtual Reality based Snow World game with certain pain medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, within subject 2x2 factorial,
      repeated measures study. Research participants will play two versions of the Virtual Reality
      based video game &quot;Snow World&quot; and be given thermal and electrical stimulus. Each of two
      study visits will be identical with the exception of whether or not the participant will
      receive an iv infusion of a low dose pain medication or a saline placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Pain responses between placebo and the low-dose pain medication while playing Snow World. We will assess pain responses with subjective questionnaires concerning the participant's experience while playing Snow World.</measure>
    <time_frame>Conclusion of 120 study visits. Each participant will spend a total of 8 hours with us.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Virtual Reality Therapy</condition>
  <arm_group>
    <arm_group_label>Low-dose pain medication</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>80min IV infusion of a low-dose pain medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>saline placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>80min IV infusion of a saline placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low-dose pain medication (Ketalar) and saline placebo</intervention_name>
    <arm_group_label>Low-dose pain medication</arm_group_label>
    <arm_group_label>saline placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and females between the age of 18 and 60 years

          -  Ability to communicate orally

          -  Ability to read and understand English

          -  Body Mass Index between 20-35

        Exclusion Criteria:

          -  Women who are pregnant, trying to become pregnant, or who are breastfeeding

          -  History of alcohol or substance abuse

          -  Major medical illness; including history of migraine headaches, seizures, brain
             injury, or peripheral neuropathy

          -  Current use of analgesics including acetaminophen, non-steroidal anti-inflammatories,
             or opioids

          -  Predisposition to severe motion sickness

          -  Unusual sensitivity or lack of sensitivity to pain

          -  Urine toxicology positive for opioids or benzodiazepines
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Sharar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Hoffer, BA</last_name>
    <phone>206-616-3075</phone>
    <email>hoffer@uw.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Hoffer, BA</last_name>
      <phone>206-616-3075</phone>
      <email>hoffer@uw.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 25, 2013</lastchanged_date>
  <firstreceived_date>April 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Sam Sharar</investigator_full_name>
    <investigator_title>Study Principal Investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
